SubHero Banner

Prezista® (darunavir) – Expanded indication

July 18, 2016 – Janssen Therapeutics announced the FDA approval of an expansion to the prescribing information for Prezista (darunavir) to include dosing recommendations for pregnant women with human immunodeficiency virus (HIV-1) and results from a study investigating the use of Prezista during pregnancy and the postpartum period.

Download PDF